Critical Survey: Absci (ABSI) & The Competition

Absci (NASDAQ:ABSI) is one of 847 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Absci to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Insider and Institutional Ownership

52.0% of Absci shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Absci and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Absci	N/A	N/A	N/A
Absci Competitors	-14,339.21%	-509.11%	-45.42%

Analyst Ratings

This is a summary of recent recommendations for Absci and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1	0	10	0	2.82
Absci Competitors	9766	14997	45286	1578	2.54

Absci presently has a consensus target price of $14.56, indicating a potential upside of 37.71%. As a group, “Biotechnology” companies have a potential upside of 92.40%. Given Absci’s rivals higher possible upside, analysts clearly believe Absci has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Absci and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Absci	$1.56 million	N/A	-13.21
Absci Competitors	$105.26 million	-$42.92 million	-9.94

Absci’s rivals have higher revenue, but lower earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Absci has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Comparatively, Absci’s rivals have a beta of 0.90, meaning that their average stock price is 10% less volatile than the S&P 500.

Summary

Absci beats its rivals on 7 of the 12 factors compared.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.